Filing Flows

Filing Flows › Castle Biosciences (CSTL) › Next earnings date

Castle Biosciences (CSTL) earnings: beat the estimate

Castle Biosciences (CSTL) reported on Nov 5, 2026 and beat the EPS estimate: −$0.13 against −$0.35 (+62.4%). Revenue was $103M for Q3 2026, +24% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+62.4% vs estimate
Beat rate80%

The last report

Castle Biosciences reported revenue of $103M for the third quarter 2026 (+24% Y/Y), net loss $4.1M: Non-Dermatologic $55.0M, Dermatologic $47.9M. How it makes money → · Every quarter →

Castle Biosciences: EPS against the estimate, last 5 reportsCastle Biosciences: EPS against the estimate, last 5 reportsEstimateReported−$0.51−$0.02Nov 25−$0.26−$0.08Feb 26−$0.49−$0.49May 26−$0.41−$0.07Jul 26−$0.35−$0.13Nov 26
Latest (Nov 26): Estimate −$0.35, Reported −$0.13.

Castle Biosciences' latest quarter

Castle Biosciences, Q3 2026: revenue $103M (+24% year over year), operating margin -2.7%, net loss $4.1M, operating cash flow $19.7M. The chart follows the revenue to costs, profit and cash.

Questions

Did Castle Biosciences beat earnings?

Castle Biosciences (CSTL) reported on Nov 5, 2026 and beat the EPS estimate: −$0.13 against −$0.35 (+62.4%).

When does CSTL report earnings?

The next date is not set yet.

Does Castle Biosciences usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.